Everything drug pricing and policy, every day
And how one pharmaceutical company expects to see revenue spike ... by slashing the list price of its medicine
The Jan. 1 pricing decisions for the 10 best-selling medicines might surprise you
And a critical 2026 trend -- dropping list prices on blockbuster drugs -- has begun with a 40%+ cut to Imbruvica’s price
And the results of the “Nobody Knows” Prediction Contest
Plus, a rosy AARP survey suggests that Medicare “negotiations” will lower out-of-pocket costs. The truth is likely to be more complicated.
And introducing the first annual ‘Nobody Knows’ Prediction Contest
And Pfizer’s take on the pharm-to-table opportunity in obesity: ‘Multiples of what we were expecting’
And Pfizer offers few new details on how the MFN deal will impact the company’s bottom line next year
